CIK: 0001964437
Total reported value
$552.2M
Reporting period: 2026-03-31 · Number of holdings: 21
Saturn V Capital Management LP disclosed 21 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $552.2M and a quarterly turnover rate of 41.6%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "S"
Saturn V Capital Management LP's disclosed holdings carry a Herfindahl concentration index of 0.073 — mathematically equivalent to about 14 equally-sized positions, close to its 21 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.75), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 2.9 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 6% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ALMS
+2.1% $39.9M
Trim ABVX
-16.4% -$27.1M
Trim COGT
-48.5% -$19.1M
Trim DYN
-46.0% -$17.5M
Add IMMX
+23.2% $18.0M
Trim JAZZ
-34.3% -$11.4M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ALMS | Alumis INC | Stock-Other | 12.77% | +7.15% | +2.11% | |
| 2 | AMLX | Amylyx Pharmaceuticals INC | Stock-Other | 10.95% | +0.98% | -3.26% | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 10.94% | -5.13% | -16.40% | |
| 4 | PCVX | Vaxcyte INC | Stock-Other | 8.68% | +1.91% | +3.20% | |
| 5 | PHVS | Pharvaris N.V. | Stock-Other | 6.15% | +0.34% | +5.38% | |
| 6 | IMMX | Immix Biopharma INC | Stock-Other | 6.09% | +3.21% | +23.15% | |
| 7 | CELC | Celcuity INC | Stock-Other | 5.83% | +0.03% | -11.10% | |
| 8 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 5.58% | -2.16% | -34.31% | |
| 9 | IRON | Disc Medicine INC | Stock-Other | 5.21% | +0.86% | +50.76% | |
| 10 | XFOR | X4 Pharmaceuticals INC | Stock-Other | 4.83% | +0.57% | +11.31% | |
| 11 | COGT | Cogent Biosciences INC | Stock-Other | 4.37% | -3.56% | -48.51% | |
| 12 | MNPR | Monopar Therapeutics INC | Stock-Other | 3.43% | -0.47% | +6.12% | |
| 13 | DYN | Dyne Therapeutics INC | Stock-Other | 3.17% | -3.25% | -45.96% | |
| 14 | IVVD | Invivyd INC | Stock-Other | 2.58% | -0.93% | +41.55% | |
| 15 | CADL | Candel Therapeutics INC | Stock-Other | 2.57% | +2.57% | NEW | |
| 16 | OCS | Oculis Holding AG | Stock-Other | 2.49% | +0.60% | — | |
| 17 | OVID | Ovid Therapeutics INC | Stock-Other | 1.68% | +0.93% | +66.67% | |
| 18 | IKT | Inhibikase Therapeutics INC | Stock-Other | 1.18% | -0.27% | +0.17% | |
| 19 | ✓ | Zura Bio LTD | Stock-Other | 0.80% | +0.80% | NEW | |
| 20 | ANRO | Alto Neuroscience INC | Stock-Other | 0.36% | +0.36% | NEW | |
| 21 | MSLE | Satellos Bioscience INC | Stock-Other | 0.36% | +0.36% | NEW |
Performance for Q3 2026
+9.9%
Performance Last 4 Quarters
+124.1%
Based on 73% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 21 | $552.2M | 42 | |
| 2025-12-31 | 20 | $544.9M | 58 | |
| 2025-09-30 | 17 | $456.0M | 100 | |
| 2025-06-30 | 24 | $246.8M | 0 | |
| 2025-03-31 | 21 | $198.2M | 0 | |
| 2024-12-31 | 24 | $255.4M | 0 | |
| 2024-09-30 | 25 | $279.8M | 0 | |
| 2024-06-30 | 26 | $264.6M | 0 | |
| 2024-03-31 | 21 | $249.4M | 0 | |
| 2023-12-31 | 23 | $261.2M | 0 | |
| 2023-09-30 | 20 | $238.9M | 0 | |
| 2023-06-30 | 20 | $180.3M | 0 | |
| 2023-03-31 | 18 | $133.9M | 0 | |
| 2022-12-31 | 19 | $120.5M | 0 |
Saturn V Capital Management LP's most significant position changes for 2026-03-31: Sold out: Ocular Therapeutix INC (OCUL); New buy: Candel Therapeutics INC (CADL); Sold out: Centessa Pharmaceuticals-adr (260); New buy: Zura Bio LTD; New buy: Alto Neuroscience INC (ANRO).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALMS | Alumis INC | +7.2% | +2.11% | Add |
| 2 | IMMX | Immix Biopharma INC | +3.2% | +23.15% | Add |
| 3 | PCVX | Vaxcyte INC | +1.9% | +3.20% | Add |
| 4 | AMLX | Amylyx Pharmaceuticals INC | +1% | -3.26% | Trim |
| 5 | OVID | Ovid Therapeutics INC | +0.9% | +66.67% | Add |
| 6 | IRON | Disc Medicine INC | +0.9% | +50.76% | Add |
| 7 | OCS | Oculis Holding AG | +0.6% | — | Unchanged |
| 8 | XFOR | X4 Pharmaceuticals INC | +0.6% | +11.31% | Add |
| 9 | PHVS | Pharvaris N.V. | +0.3% | +5.38% | Add |
| 10 | CELC | Celcuity INC | 0% | -11.10% | Trim |
| 11 | IKT | Inhibikase Therapeutics INC | -0.3% | +0.17% | Add |
| 12 | MNPR | Monopar Therapeutics INC | -0.5% | +6.12% | Add |
| 13 | IVVD | Invivyd INC | -0.9% | +41.55% | Add |
| 14 | JAZZ | Jazz Pharmaceuticals plc | -2.2% | -34.31% | Trim |
| 15 | DYN | Dyne Therapeutics INC | -3.3% | -45.96% | Trim |
| 16 | COGT | Cogent Biosciences INC | -3.6% | -48.51% | Trim |
| 17 | ABVX | Abivax Sa-adr | -5.1% | -16.40% | Trim |
| 18 | OCUL | Ocular Therapeutix INC | — | EXIT | Sold out |
| 19 | CADL | Candel Therapeutics INC | — | NEW | New buy |
| 20 | 260 | Centessa Pharmaceuticals-adr | — | EXIT | Sold out |
| 21 | ✓ | Zura Bio LTD | — | NEW | New buy |
| 22 | ANRO | Alto Neuroscience INC | — | NEW | New buy |
| 23 | MSLE | Satellos Bioscience INC | — | NEW | New buy |
| 24 | IVA | Inventiva SA - Adr | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-13 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-09 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001965552
Total reported value
$552.2M
55 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001653199
Total reported value
$552.3M
99 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001701132
Total reported value
$552.4M
215 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001727492
Total reported value
$1.5B
28 stks
2026-03-31
2 of the top 5 holdings overlap, including Abivax Sa-adr
CIK 0001776382
Total reported value
$280.6M
6 stks
2026-03-31
2 of the top 5 holdings overlap, including Pharvaris N.V.
CIK 0001839435
Total reported value
$903.6M
29 stks
2026-03-31
2 of the top 5 holdings overlap, including Abivax Sa-adr